1. Home
  2. TBPH vs SIBN Comparison

TBPH vs SIBN Comparison

Compare TBPH & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • SIBN
  • Stock Information
  • Founded
  • TBPH 2013
  • SIBN 2008
  • Country
  • TBPH United States
  • SIBN United States
  • Employees
  • TBPH N/A
  • SIBN N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • SIBN Medical/Dental Instruments
  • Sector
  • TBPH Health Care
  • SIBN Health Care
  • Exchange
  • TBPH Nasdaq
  • SIBN Nasdaq
  • Market Cap
  • TBPH 699.0M
  • SIBN 717.0M
  • IPO Year
  • TBPH N/A
  • SIBN 2018
  • Fundamental
  • Price
  • TBPH $13.95
  • SIBN $16.29
  • Analyst Decision
  • TBPH Strong Buy
  • SIBN Strong Buy
  • Analyst Count
  • TBPH 3
  • SIBN 4
  • Target Price
  • TBPH $21.33
  • SIBN $25.75
  • AVG Volume (30 Days)
  • TBPH 602.7K
  • SIBN 338.7K
  • Earning Date
  • TBPH 08-12-2025
  • SIBN 08-04-2025
  • Dividend Yield
  • TBPH N/A
  • SIBN N/A
  • EPS Growth
  • TBPH N/A
  • SIBN N/A
  • EPS
  • TBPH 0.26
  • SIBN N/A
  • Revenue
  • TBPH $77,205,000.00
  • SIBN $185,262,000.00
  • Revenue This Year
  • TBPH $78.36
  • SIBN $19.92
  • Revenue Next Year
  • TBPH N/A
  • SIBN $16.28
  • P/E Ratio
  • TBPH $54.52
  • SIBN N/A
  • Revenue Growth
  • TBPH 24.49
  • SIBN 22.93
  • 52 Week Low
  • TBPH $7.88
  • SIBN $11.70
  • 52 Week High
  • TBPH $14.55
  • SIBN $20.05
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 71.41
  • SIBN 48.65
  • Support Level
  • TBPH $13.66
  • SIBN $15.95
  • Resistance Level
  • TBPH $14.55
  • SIBN $16.88
  • Average True Range (ATR)
  • TBPH 0.46
  • SIBN 0.49
  • MACD
  • TBPH -0.02
  • SIBN 0.10
  • Stochastic Oscillator
  • TBPH 56.20
  • SIBN 60.14

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Share on Social Networks: